Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

Turnes, Juan; Díaz, Roberto; Hernandez-Guerra, Manuel; Gómez, Mariano; Castells, Lluís; Bustamante, Javier; Espinosa, M Dolores; Fernández-Castroagudín, Javier; Serrano, Trinidad; Rendón, Paloma; Andrade, Raúl; Salgado, Mercedes; Arenas, Juan; Vergara, Mercedes; Sala, Margarita; Arturo Polo, Benjamín; Martín Granizo, Ignacio; Gonzálvez, María Luisa; Viudez, Antonio.
Gastroenterol. hepatol. (Ed. impr.) ; 38(4): 263-273, abr. 2015. ilus, tab
Artigo Espanhol | IBECS (Espanha) | ID: ibc-135140

Documentos relacionados

  1. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
  2. Systemic Therapy in Metastatic Hepatocellular Carcinoma.
  3. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.
  4. Low-dose nivolumab in advanced hepatocellular carcinoma.
  5. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
  6. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
  7. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
  8. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
  9. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
  10. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.